ArticleGenes & diseases2022

Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein-protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells.

Shasha Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.